222 related articles for article (PubMed ID: 17130128)
1. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.
Jiang M; Pabla N; Murphy RF; Yang T; Yin XM; Degenhardt K; White E; Dong Z
J Biol Chem; 2007 Jan; 282(4):2636-45. PubMed ID: 17130128
[TBL] [Abstract][Full Text] [Related]
2. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis.
Jiang M; Wei Q; Wang J; Du Q; Yu J; Zhang L; Dong Z
Oncogene; 2006 Jul; 25(29):4056-66. PubMed ID: 16491117
[TBL] [Abstract][Full Text] [Related]
3. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor gene 1 enhances nutlin-3-induced apoptosis.
Lee SY; Choe YJ; Park JY; Lee SS; Kim YH; Shin SJ; Chung YJ; Kim HS
Oncol Rep; 2014 Jan; 31(1):131-6. PubMed ID: 24190574
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
8. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway.
Jiang M; Wang CY; Huang S; Yang T; Dong Z
Am J Physiol Renal Physiol; 2009 May; 296(5):F983-93. PubMed ID: 19279129
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
11. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
12. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
13. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells.
Natarajan U; Venkatesan T; Dhandayuthapani S; Dondapatti P; Rathinavelu A
Cell Signal; 2020 Nov; 75():109742. PubMed ID: 32827690
[TBL] [Abstract][Full Text] [Related]
14. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Jin L; Tabe Y; Kojima K; Zhou Y; Pittaluga S; Konopleva M; Miida T; Raffeld M
Cancer Lett; 2010 Dec; 299(2):161-70. PubMed ID: 20850924
[TBL] [Abstract][Full Text] [Related]
15. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
Lim DY; Park JH
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1060-8. PubMed ID: 19264955
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
17. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
18. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
19. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
